{"id":"temozolomide-valproic-acid","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"5-20%","effect":"Headache"},{"rate":"5-20%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Temozolomide's mechanism of action involves the formation of DNA cross-links, which prevents cancer cells from replicating. Valproic Acid, on the other hand, inhibits histone deacetylases, leading to increased histone acetylation and altered gene expression. This combination may enhance the effectiveness of temozolomide in treating certain types of cancer.","oneSentence":"Temozolomide is an alkylating agent that works by interfering with DNA replication, while Valproic Acid is a histone deacetylase inhibitor that modulates gene expression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:06.399Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glioblastoma"}]},"trialDetails":[{"nctId":"NCT03243461","phase":"PHASE3","title":"International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)","status":"UNKNOWN","sponsor":"University of Göttingen","startDate":"2018-07-17","conditions":"Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III","enrollment":167},{"nctId":"NCT02758366","phase":"PHASE2","title":"Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma","status":"TERMINATED","sponsor":"Meyer Children's Hospital IRCCS","startDate":"2016-02","conditions":"Glioblastoma (GBM), DIPG, Brainstem Glioma, Pediatric","enrollment":21},{"nctId":"NCT00437957","phase":"PHASE1","title":"Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases","status":"TERMINATED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2006-12","conditions":"Brain Metastases","enrollment":10},{"nctId":"NCT00302159","phase":"PHASE2","title":"Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-03","conditions":"High Grade Gliomas, Brain Tumors","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":72,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Temozolomide + Valproic Acid","genericName":"Temozolomide + Valproic Acid","companyName":"University of Göttingen","companyId":"university-of-g-ttingen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Temozolomide is a DNA inhibitor used in the treatment of various gliomas, including Glioblastoma, DIPG, Brainstem Glioma, Pediatric, Diffuse Spinal Glioma, and Bilateral Thalamic Glioma. Valproic Acid is a small molecule that, when combined with Temozolomide, may be studied in clinical trials for these conditions, although the exact mechanism of this combination is not specified.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}